Novartis stalwart Peter Maag to head up XDx
This article was originally published in Clinica
Executive Summary
Molecular diagnostics firm XDx has appointed Peter Maag president and CEO as it seeks to accelerate sales and expand its geographic reach. Dr Maag previously worked for Novartis since 2001, most recently as president of Novartis Diagnostics, a position he held since 2009. Brisbane, California-based XDx's lead product is the AlloMap gene expression blood test, which is used to monitor heart transplant recipients, to help predict if a patient will reject their transplanted organ. The test was cleared by the FDA in 2008. In May this year, XDx signed an agreement with LabCorp to co-develop and commercialise a diagnostic test to predict flares of systemic lupus erythematosus. More recently, XDx has closed a $15 million senior credit facility.